These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. General pharmacological properties of the human corticotropin-releasing hormone corticorelin (human). Andoh K; Kimura T; Saeki I; Tabata R; Yamazaki S; Eguchi I; Hanazuka M; Horii D; Munt PL; Davis AS Arzneimittelforschung; 1994 Jun; 44(6):715-26. PubMed ID: 8053970 [TBL] [Abstract][Full Text] [Related]
3. General pharmacological profile of the novel cholecystokinin-A antagonist loxiglumide. Saito T; Ukai K; Masuda T; Nakagawa T; Kimura K; Fujii M; Wakatsuki K; Saeki M; Kasai H Arzneimittelforschung; 1997 Dec; 47(12):1375-82. PubMed ID: 9450167 [TBL] [Abstract][Full Text] [Related]
4. General pharmacology of the new antimuscarinic compound vamicamide. Yamamoto T; Honbo T; Tokoro K; Kojimoto Y; Kodama R; Ohtsuka M; Shimomura K Arzneimittelforschung; 1995 Dec; 45(12):1274-84. PubMed ID: 8595084 [TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo mutagenicity studies on taurohyodeoxycholic acid. Tripodi AS; Feletti F; Molteni R; Germogli R Arzneimittelforschung; 1993 Aug; 43(8):897-903. PubMed ID: 8216450 [TBL] [Abstract][Full Text] [Related]
6. Reproductive toxicity of taurohyodeoxycholic acid. Feletti F; Tripodi AS; Germogli R Arzneimittelforschung; 1993 Aug; 43(8):894-7. PubMed ID: 8216449 [TBL] [Abstract][Full Text] [Related]
7. General pharmacology of recombinant human basic fibroblast growth factor. Okumura M; Yajima M; Nishimura T; Ikeda H; Nishimori T Arzneimittelforschung; 1996 Jul; 46(7):727-39. PubMed ID: 8842346 [TBL] [Abstract][Full Text] [Related]
8. General pharmacological profile of the new cognition-enhancing agent nefiracetam. Kitano Y; Makino M; Usui C; Takasuna K; Kasai Y; Hirohashi M; Tamura K; Takayama S; Kojima H; Iizuka H Arzneimittelforschung; 1994 Feb; 44(2A):199-210. PubMed ID: 8018090 [TBL] [Abstract][Full Text] [Related]
9. Chronic toxicity of taurohyodeoxycholic acid in rats. De Bernardi di Valserra M; Tripodi AS; Contos S; Mattaboni P; Germogli R Arzneimittelforschung; 1993 Aug; 43(8):880-7. PubMed ID: 8216447 [TBL] [Abstract][Full Text] [Related]
11. Chronic toxicity of taurohyodeoxycholic acid in dogs. Feletti F; Tripodi AS; De Bernardi di Valserra M; Germogli R Arzneimittelforschung; 1993 Aug; 43(8):888-93. PubMed ID: 8216448 [TBL] [Abstract][Full Text] [Related]
12. General pharmacology of loracarbef in animals. Shetler T; Bendele A; Buening M; Clemens J; Colbert W; Deldar A; Helton D; McGrath J; Shannon H; Turk J Arzneimittelforschung; 1993 Jan; 43(1):60-70. PubMed ID: 8447851 [TBL] [Abstract][Full Text] [Related]
13. General pharmacology of the new non-xanthine adenosine A1 receptor antagonist (+)-(R)-[(E)-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)acryloyl]-2- piperidine ethanol. Terai T; Kusunoki T; Kita Y; Yoshida K; Akahane A; Shiokawa Y; Kohno Y; Horiai H; Mori J; Mine Y; Kohsaka M Arzneimittelforschung; 1996 Feb; 46(2):185-91. PubMed ID: 8720311 [TBL] [Abstract][Full Text] [Related]
14. Effect of taurohyodeoxycholic acid on biliary lipid secretion in man: preliminary report. Loria P; Bozzoli M; Angelico M; Bertolotti M; Carubbi F; Concari M; Baiocchi L; Nistri A; Della Guardia P; Romani M; Carulli N Ital J Gastroenterol; 1996 Sep; 28(7):391-2. PubMed ID: 8937941 [TBL] [Abstract][Full Text] [Related]
15. Effect of taurohyodeoxycholic acid on biliary lipid secretion in humans. Loria P; Bozzoli M; Concari M; Guicciardi ME; Carubbi F; Bertolotti M; Piani D; Nistri A; Angelico M; Romani M; Carulli N Hepatology; 1997 Jun; 25(6):1306-14. PubMed ID: 9185744 [TBL] [Abstract][Full Text] [Related]
16. Effect of taurohyodeoxycholic acid, a hydrophilic bile salt, on bile salt and biliary lipid secretion in the rat. Angelico M; Baiocchi L; Nistri A; Franchitto A; Della Guardia P; Gaudio E Dig Dis Sci; 1994 Nov; 39(11):2389-97. PubMed ID: 7956608 [TBL] [Abstract][Full Text] [Related]
17. Changes in biliary lipid secretion and cholic acid kinetics induced by diet, diet plus simvastatin and diet plus ursodeoxycholic acid in obese subjects. Mazzella G; Cipolla A; Villanova N; Polimeni C; Sipahi A; Parini P; Fusaroli P; Festi D; Roda E Ital J Gastroenterol; 1995; 27(8):441-5. PubMed ID: 8775472 [TBL] [Abstract][Full Text] [Related]
18. General pharmacology of [2,2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2,3- dihydro-1H-pyrrolizine-5-yl]-acetic acid in experimental animals. Algate DR; Augustin J; Atterson PR; Beard DJ; Jobling CM; Laufer S; Munt PL; Tries S Arzneimittelforschung; 1995 Feb; 45(2):159-65. PubMed ID: 7710439 [TBL] [Abstract][Full Text] [Related]
19. General pharmacology of indole [2',3':3,4]pyrido[2,1-b]quinazolinium- 5,7,8,13-tetrahydro-14-methyl-5-oxo-chloride, a new anti-dementia agent. Park CH; Choi SH; Kim CH; Seo JH; Koo JW; Rah JC; Kim HS; Jeong SJ; Joo WS; Lee YJ; Kim YS; Kim MS; Suh YH Arzneimittelforschung; 2003; 53(6):393-401. PubMed ID: 12872609 [TBL] [Abstract][Full Text] [Related]
20. General pharmacology of cis-malonato[4R,5R)-4,5-bis-(aminomethyl)-2-isopropyl-1,3- dioxolane]platinum(II). Kim DK; Ahn JS; Ryu G; Kim KH; Park CW; Kim MS; Chung MH; Shin SG; Suh YH; Kim YS Arzneimittelforschung; 1994 Sep; 44(9):1080-8. PubMed ID: 7986249 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]